- Home
- TJX vs AZN Comparison
TJX vs AZN Comparison
Compare TJX & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJX | AZN |
|---|---|---|
| Founded | 1962 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6B | 316.4B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | TJX | AZN |
|---|---|---|
| Price | $165.51 | $182.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $169.00 | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 1.9M |
| Earning Date | 05-20-2026 | 04-29-2026 |
| Dividend Yield | 1.23% | ★ 1.73% |
| EPS Growth | ★ 14.32 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $29,078,407,000.00 | N/A |
| Revenue This Year | $6.75 | $10.34 |
| Revenue Next Year | $5.81 | $6.43 |
| P/E Ratio | $138.13 | ★ $31.91 |
| Revenue Growth | ★ 6.04 | N/A |
| 52 Week Low | $119.84 | $68.62 |
| 52 Week High | $170.00 | $212.71 |
Technical Indicators
Market Signals| Indicator | TJX | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 51.53 |
| Support Level | $152.63 | $180.98 |
| Resistance Level | $165.82 | $191.50 |
| Average True Range (ATR) | 3.24 | 2.97 |
| MACD | 0.02 | 0.36 |
| Stochastic Oscillator | 65.05 | 72.80 |
Price Performance
Historical ComparisonAbout TJX TJX Companies Inc. (The)
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.